<DOC>
	<DOCNO>NCT02556450</DOCNO>
	<brief_summary>Despite advance care , prognosis remain poor overt Heart Failure ( HF ) develop . Prevention efficient direct toward patient risk mechanistically target patient likely respond . An increase myocardial possibly vascular collagen content ( fibrosis ) may major determinant transition HF . In patient hypertension diabetes , two important risk-factors HF , change blood marker fibrosis occur clinically overt HF develops . These marker also related prognosis . In general population , Galectin-3 ( Gal-3 ) , potential marker fibrosis , associate cardiovascular ( CV ) risk factor , predicts development HF . In animal model , Gal-3 key mediator aldosterone-induced CV renal fibrosis dysfunction . The investigator hypothesize mineralocorticoid receptor antagonist ( MRA ) , spironolactone , may prevent HF act extracellular matrix remodelling , especially patient active fibrogenesis , identify high Gal-3 level . The benefit/risk ratio spironolactone might superior patient higher compare low plasma concentration Gal-3 . Main objective investigate whether spironolactone favourably alter extra-cellular matrix remodelling , assess change fibrosis biomarker Procollagen Type III N-Terminal Peptide ( PIIINP ) , patient increase risk develop heart failure whether effect great patient increase plasma concentration Gal-3 .</brief_summary>
	<brief_title>Bioprofiling Response Mineralocorticoid Receptor Antagonists Prevention Heart Failure</brief_title>
	<detailed_description>The investigator hypothesize mineralocorticoid receptor antagonist ( MRA ) , spironolactone , may prevent HF act extracellular matrix remodelling , especially patient active fibrogenesis , identify high Gal-3 level . The benefit/risk ratio spironolactone might superior patient higher compare low plasma concentration Gal-3 .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Mineralocorticoids</mesh_term>
	<criteria>Written inform consent obtain prior study procedure ; Age &gt; 65 year Clinical risk factor develop heart failure , either : 1 . Coronary artery disease ( h/o myocardial infarction , angioplasty coronary artery bypass ) Or 2 . At least two follow : Diabetes Mellitus require Hypoglycaemic Pharmacotherapy Receiving pharmacological treatment Hypertension Microalbuminuria Abnormal ECG ( leave ventricular hypertrophy , QRS &gt; 120msec , abnormal Qwaves ) Biological risk : NTproBNP value 125 1,000 ng/L BNP value 35 280 pg/ml ( consistent ESC guideline indicate risk HF help rule prevalent HF atrial fibrillation associate marked increase NTproBNP/BNP investigate ) Recent wound healing/inflammation : Surgical procedure , coronary , cerebral peripheral vascular event infection prior 3 month Cancer Autoimmune disease Hepatic Disease Preexisting diagnosis clinical HF Moderate/severe LV systolic ventricular dysfunction , i.e . LVEF &lt; 45 % Moderate severe valve disease ( investigators opinion ) eGFR &lt; 30ml/min Serum potassium &gt; 5.0 mmol/L Treatment MRA loop diuretic ( furosemide , bumetanide , ethacrynic acid torasemide ) previous three month Potassium supplement potassiumsparing diuretic time enrolment . Atrial fibrillation within one month prior inclusion ( AF last &lt; 60 second ambulatory ECG monitoring permit ) â€¢ . History hypersensitivity spironolactone . Patients unable give write informed consent . Participation another interventional trial precede month Ability walk , investigator opinion , clearly limited joint disease locomotor problem rather cardiorespiratory fitness</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>